Table 1.
n | ||
---|---|---|
Age at diagnosis, y | 43 | |
Mean ± SD | 54 ± 20 | |
Median | 58 | |
Range | 13–85 | |
Gender | ||
Male | 60% | 26 |
Histology | ||
Poorly differentiated | 33% | 14 |
Classical papillary | 28% | 12 |
Follicular variant papillary | 19% | 8 |
Tall cell variant papillary | 9% | 4 |
Other papillary | 5% | 2 |
Follicular | 5% | 2 |
Hurthle cell | 2% | 1 |
Structurally evident metastases at ablation | ||
None | 7 | |
Lungs | 57% | 20 |
Mixed | 37% | 13 |
Bone | 6% | 2 |
Size of lung metastasis | 32 | |
<1 cm | 72% | 23 |
≥ 1 cm | 28% | 9 |
AJCC stage | ||
II | 42% | 18 |
IV | 58% | 25 |
FDG-PET imaging | 29 | |
Abnormal | 55% | 16 |
Normal | 45% | 13 |
Preparation for ablation | ||
rhTSH | 67% | 29 |
Thyroid hormone withdrawal | 33% | 14 |
Suppressed Tg before ablation (ng/mL)a | 34 | |
Mean ± SD | 2536.4 ± 9602.7.5 | |
Median | 9.6 | |
Range | <0.2–54 000 | |
DxWBS before ablation | ||
Positive | 44% | 19 |
131I Ablation administered activity (mCi) | ||
Mean ± SD | 195.2 ± 77 | |
Median | 155 | |
Range | 76–501 | |
RAI therapies including ablation, n | ||
Mean ± SD | 2.2 ± 1.2 | |
Median | 2 | |
Range | 1–5 | |
131I Cumulative administered activity (mCi) | ||
Mean ± SD | 558.4 ± 439 | |
Median | 501 | |
Range | 76–1805 | |
Follow-up duration, y | ||
Mean ± SD | 5.0 ± 4.2 | |
Median | 3.6 | |
Range | 1- 17 |
Abbreviation: rhTSH, recombinant human TSH; AJCC, American Joint Committee on Cancer.
Two patients had positive TgAb at RAI ablation and reverted to detectable TgAb by the end of the study.